KARAKTERISTIK EFEK SAMPING KEMOTERAPI PADA PASIEN KANKER GINEKOLOGI DI RSUP PROF. DR. I.G.N.G. NGOERAH
Abstrak
Introduction: Gynecological cancer is one of the factors contributing to the high mortality rate in women in Indonesia. Gynecological cancer is a group of malignancies that attack the female reproductive organs. One of the treatments for gynecological cancer is chemotherapy. The use of chemotherapy itself certainly has side effects for gynecological cancer patients.
Method: his study used a descriptive method with a cross-sectional design. Data were obtained from secondary data in the form of medical records of gynecological cancer chemotherapy patients at Prof. dr. I.G.N.G. Ngoerah Hospital as many as 96 samples that met the inclusion and exclusion criteria. Data analysis used a frequency distribution table.
Result: Based on the research results, cervical cancer was found with the highest percentage (50%), the stage with the highest number was stage III (46.9%), and the use of a combination of paclitaxel and carboplatin as the most chemotherapy regimen (88.5%). Side effects of chemotherapy experienced by patients included nausea (91.7%), anemia (83.3%), thrombocytopenia (69.8%), leukopenia (62.5%), diarrhea (53.1%), and vomiting (45.8%).
Discussion: It was found that the type of gynecological cancer that was most experienced by patients was cervical cancer with the highest number of stages at stage III. The combination of paclitaxel and carboplatin became the main regimen in gynecological cancer chemotherapy. Side effects experienced by gynecological cancer chemotherapy patients were found to include nausea, anemia, thrombocytopenia, leukopenia, diarrhea, and vomiting.
Conclusion: This study concluded that the majority of patients with chemotherapy side effects came with stage III cervical cancer cases and underwent treatment with a combination of paclitaxel and carboplatin. The side effects experienced by patients undergoing chemotherapy were nausea, anemia, thrombocytopenia, leukopenia, diarrhea, and vomiting.
##plugins.generic.usageStats.downloads##
Referensi
2. Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol. (2009). Mar;20(1):8-10. doi: 10.3802/jgo.2009.20.1.8. Epub 2009 Mar 31. PMID: 19471661; PMCID: PMC2676491.
3. Brahmantara, Bagus & Kartha, Ida & Budiana, I. (2020). Characteristic gynaecology-oncology patients from Obstetrics and Gynaecology Outpatient Clinic Mangusada Regional Hospital Badung reffered to Sanglah Hospital from 1st January 2016 – 31st December 2018. Bali Medical Journal. 9. 430. 10.15562/bmj.v9i2.1836.
4. Putri, R. (2017). Kualitas Hidup Pasien Kanker Ginekologi yang Menjalani Terapi. Jurnal Aisyah : Jurnal Ilmu Kesehatan, 2(1), 69 - 74. doi:https://doi.org/10.30604/jika.v2i1.34
5. Remesh, A. (2012). Toxicities of anticancer drugs and its management. Int. J. Basic Clin. Pharmacol, 1(2), 2319-2003.
6. Darmawan, E., Melani, R., & Raharjo, B. (2019). Gambaran Hubungan Regimen Dosis Danefek Samping Kemoterapi pada Pasien Kanker di RSUD Prof Dr. Margono Soekarjo Purwokerto Periode Bulan Januari-Februari Tahun 2019. Majalah Farmaseutik, 15(2), 113-122.
7. Pangribowo, S. (2019), “Beban Kanker di Indonesia”, Pusat Data Dan Informasi Kemetrian Kesehatan RI, pp. 8–9.
8. Novalia, V. (2023). Kanker serviks. GALENICAL: Jurnal Kedokteran dan Kesehatan Mahasiswa Malikussaleh, 2(1), 45-56.
9. Shurianto, L.B., Abbas, E.H. & Fasihah, I.S. (2017), “17. Karakteristik pasien karsinoma serviks berdasarkan manifestasi klinis dan histopatologi”.
10. Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., & Siegel, R. L. (2018). Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians, 68(4), 284-296.
11. Morita, SE, Prabowo, WC, & Rijai, L. (2016). Kajian Pengobatan Pasien Kanker Serviks Di RSUD Abdul Wahab Sjahranie Samarinda. Prosiding Konferensi Farmasi Mulawarman , 4 (1), 330–334. https://doi.org/10.25026/mpc.v4i1.201
12. Dewi, Ratna. S., Sari, L, dan Rabiah. (2012). Faktor yang Mempengaruhi Keterlambatan Klien Kanker Serviks Memeriksakan Diri ke Pelayanan Kesehatan. Jurnal Penelitian Kesehatan. Vol. 10 No. 1. Hal 3.
13. National Comprehensive Cancer Network. (2013). NCCN Clinical Practice Guidelines – Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.2. 2013. National Comprehensive Cancer Network Web site.http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Diakses pada 11 September 2024
14. Santoso, C., & Askandar, B. (2011). Keberhasilan Kemoterapi Neoajuvan Cisplatin-Vincristine-Bleomycin dan Paclitaxel-Caboplatin Ditinjau dari Penilaian Operabilitas Kanker Serviks IIB. Majalah Obstetri & Ginekologi, 19(3).
15. Birgegård, G., Aapro, M. S., Bokemeyer, C., Dicato, M., Drings, P., Hornedo, J., & van Biesen, S. (2005). Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology, 68(Suppl. 1), 3-11.
16. Widayati, F. (2017). Gambaran Anemia Pada Pasien Kanker Ginekologi Yang Menjalani Kemoterapi Tahun 2016 Di RSUP Dr Sardjito (Doctoral Dissertation, Universitas Alma Ata Yogyakarta).
17. Cheng, K., Zhao, F., Gao, F., Dong, H., Men, H. T., Chen, Y., & Liu, J. Y. (2012). Factors potentially associated with chemotherapy-induced anemia in patients with solid cancers. Asian Pacific Journal of Cancer Prevention, 13(10), 5057-5061.
18. Madeddu, C., Neri, M., Sanna, E., Oppi, S., & Macciò, A. (2021). Experimental drugs for chemotherapy-and cancer-related anemia. Journal of Experimental Pharmacology, 593-611.
19. Kuter, D. J. (2022). Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica, 107(6), 1243.
20. Jang, J., Kim, H. K., Cho, B. C., Lee, K. H., Yun, H. J., Woo, I. S., & Shin, J. W. (2017). Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology, 79, 873-880
21. Wang, J., Zhou, P., Han, Y., & Zhang, H. (2021). Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction. Translational Oncology, 14(4), 101022.
22. Lee, C. K., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., & Friedlander, M. (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British journal of cancer, 105(3), 360-365.
23. Akin, J. M., Waddell, J. A., & Solimando Jr, D. A. (2014). Paclitaxel and carboplatin (TC) regimen for ovarian cancer. Hospital Pharmacy, 49(5), 425- 431.
24. Charles, A., Dewayani, B. M., Sahiratmadja, E., Winarno, G. N., & Susanto, H. (2016). Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. Universa Medicina, 35(3), 165- 170.
25. Sutarmanto, E., EMSutrisna, M. K., & Karuniawati, H. (2020). Identifikasi Adverse Drug Reaction Dan Efektivitas Penanganannya Pada Pasien Kanker Ovarium Di Rsud Dr. Moewardi Surakarta (Doctoral dissertation, Universitas Muhammadiyah Surakarta).
26. Tukan, L. A. P., Herawati, F., Kirtishanti, A., Yulia, R., & Octavia, S. K. (2024). Studi Penggunaan Kemoterapi pada Pasien Kanker Serviks di RSPAL Dr. Ramelan Surabaya: Study of the Use of Chemotherapy in Cervical Cancer Patients at RSPAL Dr. Ramelan Surabaya. Jurnal Sains dan Kesehatan, 6(3), 353-360.
27. Mustian, K. M., Devine, K., Ryan, J. L., Janelsins, M. C., Sprod, L. K., Peppone, L. J., & Morrow, G. R. (2011). Treatment of nausea and vomiting during chemotherapy. US oncology & hematology, 7(2), 91.
28. Benson III, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson Jr, J. A., & Wadler, S. (2004). Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology, 22(14), 2918-2926.
29. Fathonah, R. (2018). Identifikasi Efek Samping Kemoterapi Pada Penderita Kanker Di Yayasan Kanker Sindonesia Mulyorejo (Disertasi Doktor, Universitas Muhammadiyah Surabaya).
30. McQuade, R. M. et al. (2016) ‘Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments’, Frontiers in Pharmacology, 7(NOV), pp. 1–14.
